BrightSpring Health announces Onco360 selected as partner for OJEMDA

BrightSpring Health Services (BTSG) announces its company, Onco360, one of the nation’s largest independent oncology pharmacies, is being selected as a pharmacy partner by Day One Biopharmaceuticals (DAWN) for OJEMDA, a cutting-edge treatment for children diagnosed with certain central nervous system tumors. The FDA-approved treatment is specifically used for patients six months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. “We’re proud of the work that Onco360 is doing to improve the lives of adults and children battling cancer,” said BrightSpring’s President and CEO, Jon Rousseau. “They are partnering at the forefront of pharmaceutical innovation and their pharmacy collaboration with Day One Biopharmaceuticals for OJEMDA is evidence of their commitment to administering best-in-class oncology medications.”